| Predicate |
Object |
| assignee |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_2e3830f35387a1c32061dea3ee310851
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_41518ba53aaa1f3472837e42105cb8e7 |
| classificationCPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-04
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-124
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K2035-122
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-23
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-51
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N2501-515 |
| classificationCPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C12N5-0636 |
| classificationIPCAdditional |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-12 |
| classificationIPCInventive |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K35-14
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P37-06
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61P35-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N5-0783 |
| filingDate |
2004-06-10-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor |
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f431de515f342879fd9c26eb1cc47a0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_62096a98cb585e3b8b3ec73b9a3fdd0b
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ea780be1e1c8ee96f227d424eaa4b927
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_8fe9e824afd11be5e8842b23af404bd0
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b61f0e119c086bf0c102587f03ae6c00 |
| publicationDate |
2005-01-13-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber |
CA-2529244-A1 |
| titleOfInvention |
Rapamycin resistant t cells and therapeutic uses thereof |
| abstract |
Methods for generating highly enriched Thl/Tcl and Th2/Tc2 functions are described. In particular, the generation of these functions are attained by the addition of an immune suppression drug, rapamycin or a rapamycin derivative compound. In addition to enhanced purity of T cell function, the T cells generated in rapamycin also express molecules that improve immune T cell function such as CD28 and CD62L. Such rapamycin generated functional T cell subsets may have application in the prevention or treatment of GVHD after allogeneic hematopoietic stem cell transplantation, the treatment of autoimmunity, or the therapy of infection or cancer. |
| priorityDate |
2003-06-12-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type |
http://data.epo.org/linked-data/def/patent/Publication |